Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Photodynamic therapy with BF-200 ALA for lentigo maligna
2015-004111-20Phase 4Completed
- Sponsor
- Janne Räsänen
- Start
- Sep 2015
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of 5-aminolevulinic acid in lentigo maligna (LM), sponsored by Janne Räsänen. Primary endpoints: Histopathological cure of lentigo maligna and Immunohistochemical assessment of cure. Started Sep 2015; status: completed.
02
Drugs
5-aminolevulinic acid
03
Conditions
lentigo maligna (LM)
Beyond the preview
Go deeper on 2015-004111-20.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2015-004111-20.